Breast Invasive Ductal Carcinoma (IDC): Luminal A–like

Endocrine-sensitive, lower-risk biology. Many node-negative cases avoid chemotherapy based on genomic assay support.

• ER+, PR high
• HER2–
• Low Ki-67

• ER signaling
• CDK4/6 dependence

• Late recurrences; adherence to long endocrine therapy.

• Standard breast imaging surveillance; no routine body scans when asymptomatic.

• Back to Breast Invasive Ductal Carcinoma (IDC) overview
• Breast Invasive Ductal Carcinoma (IDC): Luminal B–like
• Breast Invasive Ductal Carcinoma (IDC): HER2-enriched
• Breast Invasive Ductal Carcinoma (IDC): Triple-negative (basal-like)